Autolus Therapeutics plc
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christian Martin Itin
- Full Time Employees
- 647
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- The MediaWorks London United Kingdom W12 7FP
- IPO Date
- Jun 22, 2018
- CIK
- 0001730463
- Website
- autolus.com
- Similar Companies
- Business
- Autolus Therapeutics plc (AUTL) is a United Kingdom-based early commercial-stage biopharmaceutical company that develops and commercializes programmed T cell therapies, including chimeric antigen receptor (CAR) T cell therapies, for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Founded in 2014 and headquartered at 191 Wood Lane in London, the company engineers precisely targeted, controlled and highly active autologous T cell products using proprietary modular cell programming technologies, such as chimeric antigen receptors combining tumor recognition domains with T cell activation and costimulatory modules; advanced viral vector and semi-automated manufacturing processes; and safety switches like RQR8. Its approved commercial product is AUCATZYL (obecabtagene autoleucel or obe-cel), a CD19-directed CAR T therapy for adult patients with relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukemia (B-ALL), with U.S. launch progressing and 33 authorized treatment centers as of early 2025; the pipeline features obe-cel in oncology and autoimmune studies including refractory systemic lupus erythematosus (SLE); AUTO1/22 (CARPALL), a dual CD19/CD22 CAR T in Phase 1 for r/r pediatric ALL; AUTO4 (LibrA T1) and AUTO5 targeting TRBC1 and TRBC2 respectively in Phase 1 for peripheral T-cell lymphoma; AUTO6NG (MAGNETO) in Phase 1 for r/r neuroblastoma and other GD2-positive solid tumors; and AUTO8 (MCARTY), a dual BCMA/CD19 CAR T in early studies for multiple myeloma. Autolus operates primary facilities in London and Stevenage in the UK, and Rockville, Maryland in the U.S., supporting global clinical trials and manufacturing. Recent developments include FDA approval of its biologics license application for AUCATZYL in November 2024 with PDUFA target met; a strategic 2024 collaboration with BioNTech providing $250 million in funding via equity investment and cash alongside license, option and manufacturing services agreements to advance obe-cel commercialization, AUTO1/22, AUTO6NG and binder technologies; partnerships with Cabaletta Bio in 2023 and Bristol Myers Squibb in 2022 granting access to RQR8 safety switch technology; and initial Phase 1 data for AUTO6NG and AUTO8 presented in late 2023 showing tolerability and activity.
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
Autolus Therapeutics plc (AUTL) Q1 2026 Earnings Call Transcript
Autolus Therapeutics Q1 Earnings Call Highlights
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus Therapeutics Highlights obe-cel Momentum in ALL With New Real-World ROKA and Pediatric Data
Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
Autolus Therapeutics plc (AUTL) Q4 2025 Earnings Call Transcript
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026
Autolus Therapeutics Touts $75M Year-1 Obe-cel Launch, Sees $120M-$135M Revenue in 2026
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Stock Traders Purchase Large Volume of Autolus Therapeutics Call Options (NASDAQ:AUTL)
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $8.33 Average Target Price from Brokerages